Please login to the form below

Not currently logged in

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

Eli Lilly, Vir Biotechnology and GlaxoSmithKline’s (GSK) neutralising antibodies have demonstrated positive results in a mid-stage study in low-risk COVID-19 patients.

The phase 2 BLAZE-4 trial, studying Lilly’s bamlanivimab co-administered with Vir/GSK’s VIR-7831, found that the combination therapy reduced viral load by 70% at day seven compared to placebo – the primary endpoint of the trial.

Bamlanivimab administered with VIR-7831 also demonstrated a statistically significant reduction in key virologic secondary endpoints compared to placebo.

The companies said there were no events for the secondary endpoint of COVID-19 related hospitalisation or death by day 29 in either study arm, with one patient in the treatment arm visiting an accident & emergency department for COVID-19-related symptoms.

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein – bamlanivimab is directed against the SARS-CoV-2 spike protein and is designed to block viral attachment and entry into human cells, while VIR-7831 has the potential to both block viral entry into health cells and clear infected cells.

VIR-7831 has previously demonstrated the ability to neutralise the SARS-CoV-2 virus, which causes COVID-19, both in vitro and in vivo.

In addition, GSK and Vir announced earlier this month that VIR-7831 demonstrated an 85% reduction in the hospitalisation or death in high-risk COVID-19 patients treated early with VIR-7831 monotherapy compared to placebo, in the COMET-ICE trial.

Lilly’s bamlanivimab has already been found to reduce the risk of COVID-19 infections in residents and staff in care homes, and also to reduce the risk of hospitalisations and deaths in high-risk COVID-19 patients when combined with its other antibody etesevimab.

"The reduction in persistently high viral load is an important virology endpoint that was demonstrated in Lilly's Phase 2 BLAZE-1 trial, and subsequently validated in the phase 3 trial, to be strongly correlated with the clinical outcome of COVID-19-related hospitalisations and deaths in high-risk patients,” said Daniel Skovronsky, chief scientific officer of Lilly and president of Lilly Research Laboratories

“This virology data supports our belief that bamlanivimab and VIR-7831 together could be a promising option for COVID-19 treatment,” he added.

GSK and Vir have submitted an emergency use authorisation (EUA) application to the US Food and Drug Administration (FDA) for VIR-7831 based on the results from the COMET-ICE trial.

Bamlanivimab is authorised under an EUA for the treatment of high-risk mild-to-moderate COVID-19 in adults  – and paediatric patients who are at least 12 years of age and weigh at least 40kg – who have tested positive for the virus.

Lilly, GSK and Vir said they ‘anticipate’ engaging with regulatory authorities across the globe – including the FDA – regarding the potential co-administration of bamlanivimab and VIR-7831 for the treatment of COVID-19.

Article by
Lucy Parsons

30th March 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...